ArticleBriefings in bioinformatics2026
Cell line-specific gene network enrichment analysis for interpreting continuous phenotypes.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gene network enrichment analysis (GNEA) offers a robust approach for interpreting the complex molecular mechanisms underlying phenotypic variability. Despite its utility, prevailing GNEA methodologies are predominantly optimized for binary phenotypes, leading to substantial information loss when applied to continuous biological traits such as drug sensitivity, cancer progression, etc. Additionally, traditional enrichment strategies often exhibit conceptual inconsistency between their null models and test hypotheses, as they rely on permuting phenotype labels rather than genes. To address these limitations, we introduce cell line-specific gene network enrichment analysis (CellGNEA), a computational strategy designed to identify pathway-level molecular interactions associated with continuous phenotypes in a cell line-specific manner. CellGNEA constructs gene regulatory networks tailored to individual cell lines and assesses molecular interplays within these networks by integrating multiple network-derived metrics, including clustering coefficient, PageRank, and regulatory effects. Associations between gene networks and continuous phenotypes are quantified using a Kolmogorov-Smirnov-based statistic, with statistical significance determined via a gene permutation strategy that aligns the null model with the tested hypothesis. Monte Carlo simulation studies indicate that CellGNEA exhibits robustness and enhanced sensitivity in detecting network enrichment linked to continuous phenotypes. Applications of CellGNEA to drug sensitivity-specific gene networks enable the identification of leukemia-related pathways with molecular interactions significantly associated with therapeutic response. Notably, our analysis revealed that imatinib, quizartinib, and ruxolitinib consistently correlate with network-level remodeling across acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia pathways, and identified resistance-associated genes including PTPN11, MS4A1, and BTK. Overall, CellGNEA establishes a systematic, scalable framework for functional network analysis of continuous phenotypes, facilitating comprehensive characterization of cell line-specific biological properties and providing valuable insights for systems biology and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.